Abstract. In myocardial ischemia-reperfusion injury (MIRI), increased activity of the c-Jun N-terminal kinase (JNK) pathway and the activation of platelets that leads to the formation of platelet-leukocyte aggregates (PLAs) have been observed. It was hypothesized that ischemic postconditioning in MIRI exerts cardioprotective effects by altering JNK activity, which in turn leads to reduced PLA levels. A total of 60 rats were randomly divided into 6 groups (n=10 for each group): i) Control; ii) ischemia-reperfusion injury alone; iii) ischemia-reperfusion with postconditioning (PostC group), iv) treatment with the JNK inhibitor -SP600125; v) postC and treatment with anisomycin; and vi) treatment with the JNK activator-anisomycin. Subsequently, the levels of PLA, infarct size, myocardial injury markers (creatinine kinase -muscle/brain and troponin I) and were measured. Western blotting was used to determine the protein expression of phosphorylated-JNK. MIRI led to increased myocardial infarct size that was associated with raised troponin I and creatine kinase-muscle/brain.

MIRI was able to increase the expression of phosphorylated JNK. These effects were significantly reduced by ischemic postC or by treatment with SP600125. By contrast, the addition of anisomycin attenuated these protective effects. JNK is a critical mediator of MIRI. Ischemic postC can reduce the level of PLA during reperfusion by inhibiting the phosphorylation of JNK MAPK, thereby reducing MIRI. Pharmacological inhibition and activation of JNK can improve and reduce cardioprotective effects, respectively. These results explained the mechanism of the cardioprotection of postC and provided novel insight and target for the therapeutic strategy of MIRI.

Introduction

Myocardial ischemia-reperfusion injury (MIRI) frequently occurs after the ischemic myocardium is treated. When MIRI occurs, the degree of myocardial damage is aggravated and the infarct area expands. The inflammatory response is one of the main factors causing reperfusion injury following acute myocardial ischemia (1). Inflammation is modulated by a number of factors including inflammatory mediators and inflammatory cells that promote myocardial damage from ischemia injury to reperfusion injury.

In acute myocardial infarction (AMI), platelets are activated and can interact with leukocytes, thereby forming platelet-leukocyte aggregates (PLAs). Increased PLA levels may be an indicator of thrombus burden and pro-inflammatory response (2) and has been observed in a variety of cardiovascular diseases, including unstable angina and AMI (3,4). Reperfusion therapy is the cornerstone for salvaging the myocardium, but it can induce damage to the working myocardium via ischemia-reperfusion (I/R) injury. Postconditioning, defined as brief periods of reperfusion alternating with re-occlusion applied during the very early min of reperfusion,
has been demonstrated to be protective against MIRI (5,6) and therefore may reduce myocardial infarct size, but its underlying mechanism is incompletely elucidated.

The c-Jun N-terminal kinase (JNK) is a member of the mitogen activated protein kinase (MAPK) superfamily. Previous experiments have demonstrated the role of the JNK signaling pathway by increasing JNK expression in MIRI (7-9). However, whether postischemic conditioning exerts its cardio-protective effects by altering the JNK signaling pathway and the levels of PLA have not been examined.

In the present study, a rat model of myocardial ischemia reperfusion in vivo was established. The expression of phosphorylated P38 MAPK and PLA was observed following postconditioning treatment, and the effect was investigated using specific inhibitors of P38 MAPK (SP 600125) and as well as activators of P38 MAPK (anisomycin). Furthermore, the present study aimed to investigate the role of P38 MAPK in signal transduction of postconditioning, as well as its effect on PLA expression.

Materials and methods

Materials. A total of 60 male Sprague Dawley rats (8 weeks old; weight, 250-280 g) were purchased from Beijing Wei Tong Li Hua Experimental Animal Co., Ltd. (Beijing, China). The rats were housed in an environment with a maintained temperature of 22°C, a relative humidity of 50±15% and a 12-h light/dark cycle. All rats had free access to standard chow and water. The present study conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23; revised 1996) and was approved by the Research Commission on Ethics of the Affiliated Yantai Yuhuangding Hospital of Qingdao University (Yantai, China). For measuring markers of myocardial damage, creatine kinase-muscle/brain (CK-MB) and troponin (TnI) kits were purchased from Merck KGaA (Darmstadt, Germany). The erythrocyte lysate was purchased from BD Biosciences, Franklin Lakes, (NJ, USA). Cluster of differentiation (CD)45 and CD41a were purchased from BD Biosciences, Franklin Lakes, (NJ, USA) and the corresponding secondary antibody was from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA).

Myocardial ischemia reperfusion model. The rats were anesthetized with an initial intra-peritoneal injection of sodium pentobarbital (0.23 ml/100 g) and were then intubated and ventilated using a rodent respirator. A ligature was inserted under the anterior descending branch of the left coronary artery (LAD), and the model was constructed by ligating the LAD for 30 min and then loosening the knot of the LAD. Different drugs, including DMSO (0.8 ml; 10%), SP600125 (6 mg/kg in 0.8 ml of 10% DMSO) and anisomycin (2 mg/kg in 0.8 ml of 10% DMSO) were injected into the right jugular vein 5 min following reperfusion. Then 3-4 ml blood was drawn from the carotid artery cannula and different treatments were given according to the measured indexes.

Experimental protocols. A total of 60 rats were randomly allocated to one of the 6 groups (n=10) as follows: i) The sham group; ii) ischemia-reperfusion (I/R) group; iii) post-conditioning (PostC) group; iv) JNK inhibitor SP600125 (1-JNK) group; v) anisomycin/Ani plus postconditioning (Ani + PostC) group and vi) anisomycin (Ani) group (Fig. 1).

In the sham group, the left coronary artery was isolated and threaded but not ligated and left for 30 min. A total of 0.8 ml 10% DMSO was injected into the right jugular vein 25 min following ischemia. In the I/R group, 0.8 ml 10% DMSO was injected into the right jugular vein 25 min following ischemia. Following the end of ischemia, continuous reperfusion was resumed and performed for 3 h. In the postconditioning (PostC) group, 0.8 ml of 10% DMSO into the right jugular vein 25 min following ischemia. After the ischemia was completed, 3 cycles of 1/1 min reperfusion/reoclusion began immediately at the onset of reperfusion and continuous reperfusion was performed for 3 h. In the 1-JNK group, SP600125 (Merck KGaA; 6 mg/kg in 0.8 ml of 10% DMSO) was injected into the right jugular vein 25 min following ischemia. Following the end of ischemia, continuous reperfusion was resumed and performed for 3 h. In the Ani + PostC group, anisomycin (2 mg/kg in 0.8 ml of 10% DMSO) was injected into the right jugular vein 25 min following ischemia. At the end of ischemia, 3 cycles of 1/1 min reperfusion/reoclusion began immediately at the onset of reperfusion and continuous reperfusion was performed for 3 h. In the Ani group, anisomycin (Merck KGaA; 2 mg/kg in 0.8 ml of 10% DMSO) was injected into the right jugular vein 25 min following ischemia. Following the end of ischemia, continuous reperfusion was resumed and performed for 3 h.

Release of serum markers. The serum levels of TnI and CK-MB were analyzed using an automatic biochemistry analyzer with the CK-MB kit. All experiments were carried out according to the manufacturer's protocol.

Measurement of infarct size. A total of 3 h following reperfusion, the hearts from the rats were excised and maintained at -20°C for 20 min. The hearts were sliced into four sections (thickness, 2 mm) from the base to the apex for staining with triphenyltetrazolium chloride (1%) at 37°C for 15 min for measuring the area of necrosis. The myocardium of the infarct area was pale, while the active myocardium was red in color. The infarct size was expressed as the ratio of the infarct area to the total left ventricular volume.

Measurement of PLA. Flow cytometry was used to detect the level of PLA as described previously (10). Briefly, sodium citrate anticoagulant was added to 200 µl of blood followed by centrifugation at 1,000 g for 5 min at room temperature. The supernatant was discarded. A total of 6-10 times the cell volume of red blood cell lysate was added and then gently mixed. A total of 1-2 min post-mixing, the cells were lysed using Red Blood Cell Lysis Buffer (cat. no. 3702; Beyotime Institute of Biotechnology, Shanghai, China). This step was repeated until clumping was complete. Then, PBS was added. The precipitate was resuspended and centrifuged at 1,000 g for 3 min. The supernatant was discarded. A total of 200 µl paraformaldehyde (2%) was added and fixed for 60 min at room temperature. PBS
(1,600 µl) was added for 15 min, and centrifuged at 1,000 x g for 15 min at room temperature followed by resuspension with PBS for 3 times, and finally dissolved in 200 µl PBS. To each group of two tubes, CD45 (cat. no. 11-0461-82; 0.25 µg/test) and CD41-phycoerythrin (cat. no. PA5-79526; 1 µg/1x10^6 cells) were used, maintained in a dark room for 30 min and centrifuged at 1,000 x g at 4˚C for 5 min. PBS suspension was detected using a BD FACSCanto II flow cytometer and BD FACSDiva™ software (BD Biosciences).

Measurement of p-JNK MAPK. Western blot analysis was performed as previously described (11). Briefly, the left ventricular myocardium was homogenized in radioimmunoprecipitation assay lysis buffer [hepes (20 mmol/l; pH 7.7), MgCl2; 2.5 mmol/l, EDTA (0.1 mmol/l), B-glycerophosphate (20 mmol/l), dithiothreitol (0.5 mmol/l), sodium orthovanadate (0.1 mmol/l), NaCl (75 mmol/l), leupeptin (4 µg/ml), phenyl-methylsulfonyl fluoride (20 µg/ml) and Triton X-100 (0.05%; v/v)]. To quantify protein levels, equal amounts of total protein (10 µg) were loaded into lanes. Protein concentration was determined using the bicinchoninic acid method (cat. no. A53225; Pierce; Thermo Fisher Scientific, Inc.). After the separation of proteins via SDS-PAGE gel (10%) electrophoresis, the proteins were transferred to nitrocellulose membranes and incubated with antibodies against p-JNK MAPK (cat. no. sc-6254; 1:200) and β-actin (cat. no. sc-47778; 1:200; both Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 4 h at room temperature, which was followed by incubation with horseradish peroxidase-conjugated secondary antibodies (cat. no. 016-030-084; 1:1,000; Jackson ImmunoResearch Laboratories, Inc.) for 1 h at room temperature. The antigen-antibody complexes were visualized using enhanced chemiluminescence (Beyotime Institute of Biotechnology) at room temperature. The integrated optical density (IOD) of the bands were analysed using Image Pro Plus image analysis software (version 4.1; Media Cybernetics, LP, USA). The IOD was calculated by multiplying the value of the average optical density by area. The ratio of IOD values of the target protein and β-actin was used to reflect the relative level of the target protein.

Statistical analysis. The data were analysed using the statistical software package SPSS 20.0 (IBM Corp., Armonk, NY, USA) for Windows. The values are expressed as the mean ± standard error of the mean. A one-way analysis of variance followed by the SNK post hoc test or the Student’s t-test was used as appropriate to determine the differences between groups. P<0.05 was considered to indicate a statistically significant difference. All experiments were performed in triplicate.

Results

Infarct size and serum markers of myocardial damage. Initial experiments examined infarct size following AMI with the infarcted myocardium stained white and the viable myocardium stained red (Fig. 2). Compared with the sham group, the infarct size was 42.2% in the I/R injury group. The infarct size was significantly reduced in the postconditioning group (P<0.05) and also following application of the JNK inhibitor, SP600125 (I-JNK). Furthermore, this reduction in infarct size was abolished when the JNK activator, Ani was applied, but not when the hearts underwent postconditioning (Table I).

In the sham group the levels of CK-MB and TnI were 166±33 pg/ml and 7.8±0.5, respectively (Table I). Compared with the Sham group, the levels of CK-MB and TnI were significantly increased in the I/R injury group (P<0.05). Compared with the I/R injury group, the levels of CK-MB and TnI were significantly lower in the postconditioning group (P<0.05) and also following application of the JNK inhibitor, SP600125 (I-JNK). Furthermore, this reduction in infarct size was abolished when the JNK activator, Ani was applied, but not when the hearts underwent postconditioning (Table I).

Levels of the PLAs and p-JNK. The level of PLAs in the Sham group was 8.70±0.56, 8.99±0.56, 8.80±0.36 and 10.11±0.87 at 30 min following ischemia, and at 30, 60 min and 3 h following...
reperfusion, respectively (Table II). Ischemia-reperfusion injury led to a significant increase in PLA level 60 min and 3 h following reperfusion compared with the post-conditioning group (P<0.05). By contrast, ischemic postconditioning or application of the JNK inhibitor, SP600125, prevented the rise of PLA level at 60 min and 3 h post-reperfusion compared with the I/R injury group (P<0.05). Neither anisomycin treatment nor anisomycin with postconditioning significantly affected PLA level compared with ischemia-reperfusion conditioning (Table II and Fig. 3).

Finally, p-JNK expression was measured (Fig. 4). Compared with the I/R group, postconditioning or SP600125 significantly reduced p-JNK expression (P<0.05), while treatment with anisomycin alone significantly increased p-JNK expression (P<0.05). The treatment with anisomycin with postconditioning partially also reduced the level of PLA.

Discussion

Using an ischemia-reperfusion model in rat hearts, ischemic postconditioning reduced infarct size and prevented the rise in TnI, CK-MB, p-JNK expression and the levels of PLA. These protective effects were similarly observed using the JNK inhibitor SP600125, but the effects were abolished with the JNK activator, anisomycin.

Ischemic postconditioning is an important cardiac protective mechanism, which reduces myocardial infarct size (12), the occurrence of arrhythmias (13), and improves vascular endothelial function (14) and myocardial systolic function. In ischemia-reperfusion injury, inflammation has a critical role in mediating myocardial damage. This involves the recruitment of leukocytes and the activation of platelets, leading to enhanced interactions between P-selectin glycoprotein ligand-1, which is expressed in the leukocytes, with P-selectin, which is expressed in the platelets to form PLAs. PLA is a sensitive index of thrombus load and inflammatory burden \textit{in vivo} (1). Previous studies have demonstrated that high levels of PLA were not only positively and significantly associated with the risk of acute coronary syndrome (15) but were also closely associated with the no-reflow phenomenon (16).

Postconditioning is an important mechanism that protects against myocardial damage, reducing damage that is mediated by ischemia-reperfusion and improving cardiac contractile function. However, the molecular pathways responsible for protection against myocardial damage have not been entirely elucidated.

JNK is a member of the MAPK family that modulates multiple cellular functions, including proliferation, differentiation and apoptosis (17). JNK can be activated by ischemia and reperfusion insult. In the absence of JNK, mouse hearts subjected to ischemia-reperfusion have significantly less necrosis and apoptosis (18). On the contrary, the inhibition of JNK reduced the apoptosis of cardiomyocytes and infarct size following ischemia-reperfusion injury (19).

Nuclear factor (NF)-κB is an important transcription factor that is involved in ischemia and reperfusion injury. A recent study demonstrated that intrinsic activation of AMP-activated protein kinase modulated JNK-NF-κB signaling cascade during hypoxia and reoxygenation stress conditions. It was critical to prevent excess mitochondrial reactive oxygen production and consequent JNK signaling during reperfusion, thereby protecting against mitochondrial permeability transition pore opening, irreversible mitochondrial damage and myocardial injury (20). In the present study, at different time points of MIRI, the level of PLA gradually increased. Compared with the injury-reperfusion group, the level of PLA in the PostC and I-JNK groups was significantly reduced at 60 min and 3 h following reperfusion, which suggested that PLA (a marker of inflammation and thrombosis) was involved in the pathogenesis of MIRI. Ischemic postconditioning or inhibition of JNK reduced the level of PLA. In addition, ischemia-reperfusion injury was able to increase p-JNK expression, which was prevented by ischemic postconditioning or JNK inhibition. This result suggested that myocardial ischemia-reperfusion was able to activate the JNK signaling pathway. Ischemic postconditioning or the inhibition of JNK served a critical role in inhibiting the inflammatory response during the ischemia/reperfusion process. Based on the above results, it was speculated that the cardioprotective effect of ischemic postconditioning may
be associated with the attenuation of inflammation, which occurred during ischemia/reperfusion via the modulation of the JNK-mediated NF-κB signaling pathway. Therefore, regulating JNK activation may represent an important novel strategy in the prevention and treatment of MIRI.

Although the current study provided interesting results, there remain certain weaknesses. Firstly, MIRI is a complicated pathological process, however, only JNK MAPK signaling pathway was included in the present study, the whole signaling network was not investigated. Secondly, the infarct size in I-JNK group was significantly reduced, but

Table I. Serum markers and infarct area in all groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>CK-MB (pg/ml)</th>
<th>TnI (pg/ml)</th>
<th>Infarct area (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>166.02±33.26^a,b</td>
<td>7.79±0.54^a,b</td>
<td>0.00±0.00^a,b</td>
</tr>
<tr>
<td>Ischemia-reperfusion</td>
<td>637.31±43.99^b</td>
<td>19.67±0.66^b</td>
<td>40.17±1.77^b</td>
</tr>
<tr>
<td>Postconditioning</td>
<td>257.38±53.12^a</td>
<td>10.05±0.81^a</td>
<td>16.68±2.06^a</td>
</tr>
<tr>
<td>JNK inhibitor SP600125</td>
<td>402.10±47.94^a,b</td>
<td>14.26±1.31^a,b</td>
<td>24.62±1.58^a,b</td>
</tr>
<tr>
<td>JNK activator anisomycin and postconditioning</td>
<td>500.84±52.93^a,b</td>
<td>17.32±0.77^a,b</td>
<td>27.91±1.79^a,b</td>
</tr>
<tr>
<td>JNK activator anisomycin</td>
<td>638.34±25.87^b</td>
<td>19.96±0.72^b</td>
<td>40.62±1.59^b</td>
</tr>
</tbody>
</table>

^aP<0.05 vs. the I/R group; ^bP<0.05 vs. the post-conditioning group. CK-MB, creatine kinase muscle/bone; TnI, troponin I; JNK, c-Jun N-terminal kinase.

Table II. Expression of platelet-lymphocyte aggregates at different time points.

<table>
<thead>
<tr>
<th>Group</th>
<th>Baseline</th>
<th>30 min following ischemia</th>
<th>30 min following reperfusion</th>
<th>60 min following reperfusion</th>
<th>3 h following reperfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>7.96±0.30</td>
<td>8.70±0.56^a,b</td>
<td>8.99±0.56^a,b</td>
<td>8.80±0.36^a,b</td>
<td>10.11±0.87^a,b</td>
</tr>
<tr>
<td>Ischemia-reperfusion</td>
<td>8.06±0.23</td>
<td>23.70±2.79</td>
<td>34.78±2.79</td>
<td>42.00±2.02</td>
<td>51.03±2.02</td>
</tr>
<tr>
<td>Postconditioning</td>
<td>9.01±0.26</td>
<td>22.76±1.93</td>
<td>32.50±1.93</td>
<td>23.90±0.89^a</td>
<td>18.40±1.27</td>
</tr>
<tr>
<td>JNK inhibitor SP600125</td>
<td>8.43±0.22</td>
<td>23.90±2.06</td>
<td>32.90±2.06</td>
<td>29.57±1.46^b</td>
<td>26.64±1.18^b</td>
</tr>
<tr>
<td>JNK activator anisomycin and postconditioning</td>
<td>9.30±0.29</td>
<td>21.81±2.14</td>
<td>32.69±2.14</td>
<td>45.66±0.94^b</td>
<td>54.35±1.45^b</td>
</tr>
<tr>
<td>JNK activator anisomycin</td>
<td>9.23±0.40</td>
<td>22.20±2.82</td>
<td>32.7±2.82</td>
<td>45.70±1.69^b</td>
<td>54.80±1.40</td>
</tr>
</tbody>
</table>

^aP<0.05 vs. the I/R group; ^bP<0.05 vs. the post-conditioning group. JNK, c-Jun N-terminal kinase.

Figure 3. The level of PLAs at different time points following ischemia or reper in different groups. CD45 and CD41-Phycoerythrin were used to detect PLAs levels in each group. At the time point of baseline, 30 min following ischemia, 30, 60 min and 3 h following reper, the level of PLAs was detected by flow cytometry. Reper, reperfusion; CD, cluster of differentiation; I/R, ischemia reperfusion; Ani, anisomycin, postC, postconditioning; I-JNK, inhibitor of c-Jun N-terminal kinase; PLA, platelet-lymphocyte aggregates.

Figure 4. Expression of P-JNK MAPK in different groups. Western blot analysis of the expression of P-JNK MAPK in the sham, ischemia-reperfusion (I/R), ischemic PostC, I-JNK, and ischemic postconditioning with anisomycin (Ani+PostC) groups. Statistical analysis of levels of protein expression. ^P<0.05 vs. the I/R group; ^P<0.05 vs. the post-conditioning group. I/R, ischemia reperfusion; Ani, anisomycin, postC, postconditioning; I-JNK, inhibitor of c-Jun N-terminal kinase; p, phosphorylated.
the expression level of apoptosis associated proteins was not detected. Finally, although pharmacological inhibition of JNK has cardioprotective effects, it is not clear whether this JNK inhibitory effect will produce adverse effects in other tissues.

JNK is a critical mediator of MIRI. Ischemic postconditioning can reduce the level of PLA during reperfusion by inhibiting the phosphorylation of JNK MAPK, thereby reducing MIRI. Pharmacological inhibition and activation of JNK can improve and reduce the cardioprotective effects, respectively. The results of the present study help to explain the mechanism of the cardioprotection against MIRI of postconditioning in rats. In addition, it provided novel insight and targets for the therapeutic strategy of MIRI. JNK inhibition may represent a novel therapeutic strategy for the alleviation of MIRI.

Acknowledgements
Not applicable.

Funding
The present study was supported by grants from the National Natural Science Foundation of China (grant no. 81500271).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
FR, NM and MG performed experiments and drafted the manuscript. CZ and XS performed the experiments. LL and TL analyzed the data. JL and JS performed the animal experiments. MD and GT made substantial contributions to the design of the present study. All authors approved the final version of manuscript.

Ethics approval and consent to participate
The present study was approved by the Research Commission on Ethics of the Affiliated Yantai Yuhuangding Hospital of Qingdao University.

Patient consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

References